FDA grants expanded access for Direct Biologics' ExoFlo

By The Science Advisory Board staff writers

October 14, 2020 -- The U.S. Food and Drug Administration (FDA) granted expanded access for Direct Biologics' ExoFlo, allowing it to be used to treat patients with COVID-19-associated acute respiratory distress syndrome.

ExoFlo is an investigational new extracellular vesicle drug that is isolated from human bone marrow mesenchymal stem or stromal cells. Expanding access gives doctors the option to administer ExoFlo as a treatment to reverse disease progression in patients.

Though patients are already being enrolled in the company's phase II, placebo-controlled, randomized clinical trial EXIT COVID-19, the expanded access protocol makes ExoFlo available to a broader group of patients with severe COVID-19 who would not meet the "compassionate use" criteria.

J&J pauses COVID-19 vaccine trials
Johnson & Johnson on October 12 temporarily paused further dosing in all of its COVID-19 vaccine clinical trials, including the phase III Ensemble...
Moderna gets nod from EMA to submit marketing authorization
Moderna has received written confirmation from the European Medicines Agency (EMA) that messenger RNA (mRNA)-1273, the company's COVID-19 vaccine candidate,...
Celltrion begins clinical trial for COVID-19 mAb
Celltrion has launched a phase III clinical trial investigating CT-P59, an anti-COVID-19 monoclonal antibody (mAb) treatment candidate.
Inovio reports long-term positive results for COVID-19 vaccine
Inovio released results of a nonhuman primate study for its COVID-19 DNA vaccine, INO-4800. The vaccine protected the animals 13 weeks after vaccinations...
Direct Biologics begins phase II trial for COVID-19 ExoFlo therapy
Regenerative medical products manufacturer Direct Biologics has won approval from the U.S. Food and Drug Administration to study its ExoFlo therapy in...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter